An audit of hormonal contraceptive use in Women’s Super League soccer players; implications on symptomology by Parker, LJF et al.
 
Parker, LJF, Elliott-Sale, KJ, Hannon, MP, Morton, JP and Close, GL
 An audit of hormonal contraceptive use in Women’s Super League soccer 
players; implications on symptomology
http://researchonline.ljmu.ac.uk/id/eprint/15319/
Article
LJMU has developed LJMU Research Online for users to access the research output of the 
University more effectively. Copyright © and Moral Rights for the papers on this site are retained by 
the individual authors and/or other copyright owners. Users may download and/or print one copy of 
any article(s) in LJMU Research Online to facilitate their private study or for non-commercial research. 
You may not engage in further distribution of the material or use it for any profit-making activities or 
any commercial gain.
The version presented here may differ from the published version or from the version of the record. 
Please see the repository URL above for details on accessing the published version and note that 
access may require a subscription. 
For more information please contact researchonline@ljmu.ac.uk
http://researchonline.ljmu.ac.uk/
Citation (please note it is advisable to refer to the publisher’s version if you 
intend to cite from this work) 
Parker, LJF, Elliott-Sale, KJ, Hannon, MP, Morton, JP and Close, GL (2021) 
An audit of hormonal contraceptive use in Women’s Super League soccer 
players; implications on symptomology. Science and Medicine in Football. 
ISSN 2473-3938 
LJMU Research Online
Full Terms & Conditions of access and use can be found at
https://www.tandfonline.com/action/journalInformation?journalCode=rsmf20
Science and Medicine in Football
ISSN: (Print) (Online) Journal homepage: https://www.tandfonline.com/loi/rsmf20
An audit of hormonal contraceptive use
in Women’s Super League soccer players;
implications on symptomology
Lloyd J. Parker, Kirsty J. Elliott-Sale, Marcus P. Hannon, James P. Morton &
Graeme L. Close
To cite this article: Lloyd J. Parker, Kirsty J. Elliott-Sale, Marcus P. Hannon, James P.
Morton & Graeme L. Close (2021): An audit of hormonal contraceptive use in Women’s Super
League soccer players; implications on symptomology, Science and Medicine in Football, DOI:
10.1080/24733938.2021.1921248
To link to this article:  https://doi.org/10.1080/24733938.2021.1921248
© 2021 The Author(s). Published by Informa
UK Limited, trading as Taylor & Francis
Group.
Published online: 16 May 2021.
Submit your article to this journal 
Article views: 657
View related articles 
View Crossmark data
ARTICLE
An audit of hormonal contraceptive use in Women’s Super League soccer players; 
implications on symptomology
Lloyd J. Parker a,b, Kirsty J. Elliott-Sale c, Marcus P. Hannon a, James P. Morton a and Graeme L. Close a
aResearch Institute for Sport and Exercise Sciences, Liverpool John Moores University, Liverpool, UK; bEverton Football Club, USM Finch Farm, 
Halewood Liverpool, Liverpool, UK; cSport Health and Performance Enhancement Research Centre, Nottingham Trent University, Nottingham, UK
ABSTRACT
Purpose: To audit hormonal contraceptive use and associated symptomology in elite women’s soccer in 
England.
Methods: Seventy-five elite women’s soccer players from the Women’s Super League (WSL) completed 
a questionnaire to assess: hormonal contraceptive (HC) use or non-use, reasons for initiation and 
discontinuation and the symptoms experienced by HC and non-HC users.
Results: Twenty-eight per cent reported current HC use, with 43% having used HCs previously. 
Combined HCs accounted for 62% of total usage, with progestin-only HCs making up the remainder. 
Eighty-six per cent pre-empted negative symptoms before commencing HCs, with 38% experiencing 
adverse symptoms. Negative symptoms were most common in progestin-only HC users (63%). Eighty-six 
per cent reported benefits associated with HC usage include pain management and the ability to predict 
or control their cycles. Six non-HC users reported amenorrhea, with one medically diagnosed. Negative 
MC-related symptoms were reported by 74%, with 4% unable to train due to these symptoms. 
Unfavorable symptoms typically occurred during the first days of menstruation (59%).
Conclusion: Most WSL players do not currently use HCs (72%). Most HC users reported benefits of HC 
usage, whilst most non-HC users reported negative symptoms especially around menstruation. 
Practitioners should track players' MCs to help minimise discomfort and maximise performance.
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Introduction
In 2015, the Women’s Super League (WSL) became the first 
professional women’s soccer league in England. Since then, 
women’s soccer has grown in popularity and participation. 
The increased number of players and competitions is driving 
the need for researchers and practitioners to understand the 
potential impact of ovarian steroid hormones on training and 
performance. To capitalise on previous research in this field 
(Julian et al. 2017) and to underpin future research, we need 
to define the menstrual characteristics (i.e., hormonal contra-
ceptive [HC] use and non-use) of elite women’s soccer players.
A greater number of athletes use HCs (49.5%) compared to 
the general population (30%) (Cea-Soriano et al. 2014; Martin 
et al. 2018). HCs are exogenous steroid hormones that inhibit 
ovulation and result in consistently low levels of endogenous 
oestrogen and progesterone (Elliott-Sale and Hicks 2018). Data 
from Schaumberg et al. (2018) showed that athletes use HC for 
perceived performance benefits; however, data from a recent 
review indicated that HCs may impair performance in some 
sportswomen (Elliott-Sale et al. 2020). It is crucial to establish 
how many WSL players use a HC, their reason for usage and any 
side effects experienced, in order to ascertain their potential 
implications for players (i.e., this approach will help to minimise 
any potential negative effects on performance and maximise 
any potential positive effects on adverse menstrual cycle symp-
toms (Oxfeldt et al. 2020), thus ensuring that players can 
perform to the best of their ability on any given day, regardless 
of ovarian hormone profile).
In the absence of menstrual irregularities, non-HC users 
typically have an idealized 28-day MC, although cycles can 
vary between 21 and 35 days (Lamina et al. 2013). 
Abnormalities of the MC occur in 6–79% of sportswomen, 
with the prevalence of menstrual dysfunction varying with 
athletic discipline and level of competition (Warren and 
Perlroth 2001). Whilst menstrual function data have been col-
lected in many types of sportswomen (Cobb et al. 2003; 
Fahrenholtz et al. 2018; Hoch et al. 2009, 2011; Melin et al. 
2015; Torstveit and The Female 2005), there are limited data 
in women’s soccer (Prather et al. 2016; Reed et al. 2013; 
Sundgot-Borgen and Torstveit 2007) and currently no data on 
players in England since soccer turned professional. It is impor-
tant to determine the menstrual characteristics of non-HC users 
in order to understand their potential consequences for 
players.
The aim of this study was to audit HC and non-HC use, 
determine the reasons for initiation and discontinuation of 
HCs, and report the symptoms experienced by HC users and 
non-users, in WSL players. These data will build upon previous 
information gathered in 2015–2016 by Martin et al. (2018) in 
a diverse range of sportswomen, by providing soccer-specific 
information relevant to the professional game. These findings 
can be used by practitioners to benchmark their own players 
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and implement strategies to support players with their repro-
ductive health and associated conditions.
Methods
Participants
Between 2017 and 2018, players were recruited from the WSL. 
All 10 WSL clubs were contacted, and six clubs participated. 
Players were contacted through support staff, who took written 
informed consent and administered the questionnaires. All 
players were recruited using the same procedures; that is, no 
player or type of player was specifically targeted for recruit-
ment. Each player returned their own questionnaire in indivi-
dual, sealed envelopes. Athletes had to be >18 years old, 
contracted to a WSL club and have played at least one game 
in the WSL. Seventy-six players out of 194 in the WSL com-
pleted the questionnaire (Figure 1). All players were nullipar-
ous. The study was approved by the non-invasive ethics 
committee at Nottingham Trent University. Written informed 
consent was obtained from each player with the 
acknowledgement that their data would be used for publishing 
and fully anomymised.
Questionnaire
Data were collected using a modified version of a previously 
designed questionnaire (Martin et al. 2018). The questionnaire 
was designed to identify the self-reported: (Julian et al. 2017) 
period prevalence and characteristics of HC and non-HC users; 
(Martin et al. 2018) reasons for initiation and discontinuation of 
HCs; and (Cea-Soriano et al. 2014) perceived symptoms asso-
ciated with HC use and non-use. As such, all data reported in 
this study are ‘self-reported’ and ‘perceived’. Participants were 
required to record demographic information, age of menarche, 
competitive level, time competing at this level, and weekly 
training frequency and duration (Table 1). Participants were 
required to complete different sections of the questionnaire 
depending on HC use or non-use. The final section of the 
questionnaire required all participants to provide details on 
previous HC use, including preparation, duration of use and 
reason for discontinuation.
Total number of 
questionnaire responses 
(n=76)
Current non-HC users 













Microgynon® (n=5)     Levest (n=2)
Yasmine® (n=1) Zoely® (n=2)




Responses included in 
analysis (n=75)
Figure 1. The prevalence and characteristics of hormonal contraceptive users and non-users.IUS, intrauterine system; OC, oral contraceptive; HC, hormonal 
contraceptive.
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Data analysis
Data were analysed using Microsoft Excel. To prevent duplicate 
data, date-of-births and identical values were visually checked. 
HC and non-HC user characteristics were compared using inde-
pendent samples t-tests; the level of significance was set at 
P ≤ 0.05. All data were handled in the same way. For qualitative 
questions, a content analysis was carried out separately by two 
researchers (LP and GC) to categorise responses, whereby 
a frequency analysis was performed to elicit common themes. 
Differences between the researchers were discussed until 
a consensus was reached. Data are represented as means 
(±SD), frequencies and percentages.
Results
Period prevalence and characteristics of hormonal 
contraceptive users
The period prevalence and descriptive characteristics of HC 
users are presented in Figure 1 and Table 1. The average length 
of HC usage was 3.1 ± 3.1 years. The main reasons for choosing 
a particular HC method were: General Practitioner advice (38%), 
easiest form (20%), and friends’ recommendation (14%). Only 
55% of the players discussed their HC use with their coach or 
team doctor.
Previous hormonal contraceptive use
Of the players that did not currently use HCs, 20% reported 
previous usage. Of the players with current HC use, 19% had 
previously used a different HC formulation. The reasons for 
discontinuing or switching HC formulation are shown in 
Figure 2C.
Symptomology of hormonal contraceptive users
The frequency and prevalence of symptoms experienced by 
players using HCs are presented in Table 2. Figure 2A and 2B 
show the anticipated positive and negative side effects before 
players commenced HCs. Negative symptoms were more com-
mon in progestin-only HCs (63%) compared with combined 
HCs (23%).
Period prevalence and characteristics of non-hormonal 
contraceptive users
The period prevalence and descriptive characteristics of non- 
HC use are presented in Figure 1 and Table 1. None of the non- 
HC users used a non-hormonal IUD. The mean cycle length was 
31 ± 10 days, with 67% reporting that their cycle varied in 
length (cycle length varied by 3–63 days). Six players reported 
being amenorrhoeic and eight players reported being oligo-
menorrheic, although only one case of amenorrhea was diag-
nosed by a clinician.
Symptomology of non-hormonal contraceptive users
The frequency and prevalence of adverse symptoms for non- 
HC users are presented in Table 3. Adverse MC-related symp-
toms were reported by 74% of players, with 4% stating that 
these symptoms had prevented them from training. Reasons 
for having to miss training included ‘heavy bleed’, ‘back pain,’ 
and ‘being sick’. These issues mainly occurred during the first 
2–3 days of menstruation (59%) and in the days leading up to 
menstruation (17%). Medication was used by 19% of the 
players to deal with menstrual-related issues, with 13% using 
nonsteroidal anti-inflammatory drugs (NSAIDs) and 6% taking 
paracetamol.
Discussion
The aim of the present study was to audit HC and non-HC use in 
the WSL and to describe the associated symptomology. This 
study provides novel data on the reproductive characteristics of 
elite women’s soccer players. Less than a third of players cur-
rently use a form of HCs. From the players using HCs, 86% 
reported benefits and 38% reporting negative symptoms. 
From the non-HC using players, 74% reported negative symp-
toms and none reported benefits.
In the non-HC users, all players without menstrual irregula-
rities fulfilled the eumenorrheic criterion for cycle length 
Table 1. Characteristics for the football associations Women’s Super League 
players; hormonal contraceptive and non-hormonal contraceptive users.
Demographic 










Height (m) 1.69 ± 4.7 1.67 ± 6.1 0.405 1.68 ± 5.7
Body Mass (kg) 63.3 ± 3.6 61.7 ± 6.1 0.248 62.1 ± 5.5
Body mass index 
(kg·m2)
22.3 ± 1.0 22.1 ± 2.0 0.589 22.1 ± 1.8
Age at menarche (y) 13.5 ± 1.3 14.0 ± 1.7 0.215 13.9 ± 1.6
Duration competing 
at current level (y)
6.2 ± 3.4 5.9 ± 3.9 0.820 6.1 ± 3.8
Number of training 
sessions per week




88.1 ± 12.7 93.4 ± 19.3 0.245 92.3 ± 17.9
Total weekly training 
duration (mins)
555.1 ± 183.1 598.8 ± 205.8 0.357 587.2 ± 198.9
All data expressed as mean (SD). No significant difference existed between 
groups for any variable. Significant difference was set at P < 0.05. HC, hormonal 
contraceptive
Table 2. Sample frequency (n = 21) and prevalence of self-reported perceived 




















2 10% No period 6 29%
Weight 
gain
1 5% Less pain 5 24%
Acne 1 5% ‘Continue day’ 2 10%
Feeling 
sick
1 5% Skin 1 5%
Headache 1 5% ‘Feel faster’ 1 5%
Lighter flow 1 5%
‘Continue day’ and ‘feel faster’ are direct quotes taken from questionnaire 
responses therefore we are unable to interpret the exact meanings.
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(Lamina et al., 2013). Six players reported amenorrhea, 
although only one player was diagnosed by a clinician. Eight 
players reported oligomenorrhea, none of which were diag-
nosed by a clinician. Although our questionnaire did not 
explore the reasons behind this observation, it highlights that 
WSL players are not discussing their menstrual characteristics 
with a health-care professional. This observation is supported 
by recent data (Findlay et al. 2020; Larsen et al. 2020), which 
suggests that: (i) sportswomen have little/no medical support; 
(ii) sportswomen do not feel confident enough to disclose their 
menstrual issues with support staff; (iii) support staff often do 
not have a good understanding of the best practice to deal 
with MC/HC symptoms; and (iv) sportswomen do not have a full 
understanding about amenorrhea and their own menstrual 
function. As such, we recommend that players and support 
staff receive suitable training/education such that they have 
a good understanding of menstrual function and dysfunction, 
from both a health and performance perspective, for example, 
as a potential indicator of Relative Energy Deficiency in Sport. 
As menstrual irregularities were self-reported in this question-
naire, future research should involve medical screening/diag-
nosis to provide data on how prevalent menstrual irregularities 
are in WSL.
Nine negative symptoms were reported by non-HC users 
(Table 2), with 74% of players reporting at least one symptom. 
This is similar with the general population (Ju et al. 2014) and 
other elite athletes (Martin et al. 2018), although a study in elite 
female rugby players reported that 93% of players had negative 
MC-related symptoms (Findlay et al. 2020). A limitation of the 
present study was that it did not specifically ask if these symp-
toms could have been affected by factors other than the MC (e. 
g., a medical condition, such as endometriosis); however, data 
collected on current medication usage did not infer any of the 
players having a medical condition that would have signifi-
cantly influenced the reported symptoms. Symptoms were 
mainly experienced in the initial days of menstruation (59%), 
but also occurred in days leading up to menstruation (17%). In 
the present study, only two players reported that they missed 
training as a result of their MC symptoms, thus supporting 
previous research in elite athletes (Martin et al. 2018). Despite 
non-HC users reporting symptoms interfering with their train-
ing, there was no statistical difference between groups in the 
number of training sessions per week, average training session 
duration or total weekly training duration (Table 1). A limitation 
Figure 2. Anticipated negative symptoms before commencing hormonal contra-
ceptives (A), anticipated positive symptoms before commencing hormonal con-
traceptives (B), reasons for discontinuing or switching hormonal contraceptives 
(C). Please note that each dot represents an individual person.
Table 3. Sample frequency (n = 54) and prevalence of negative self-reported 
perceived symptoms during the menstrual cycle for non-hormonal contraceptive 
users.
Symptom Sample frequency Prevalence (%)
Cramps 38 70%
Sore back 8 15%
Tiredness 7 13%
Loss of appetite 2 4%
Sore legs 2 4%
Vomiting/feeling sick 2 4%
Mood swings 2 4%
Bloating 1 2%
Sore breasts 1 2%
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of the present study was that we did not establish the severity 
of the symptoms experienced, the frequency of missed training 
sessions, or if players trained despite feeling unable to do so. 
Findlay et al. (2020) reported that some women’s rugby players, 
no matter the severity, did not feel that their menstrual related 
symptoms were an acceptable reason to take rest or abstain 
from training. With 74% of players in the current study suffering 
from symptoms, further research is required to understand the 
frequency, severity, duration and impact of these on training, 
and if ‘soccer’ allows players to adapt their training without 
negative repercussions. Ideally, practitioners need to allow flex-
ibility in training sessions to accommodate the most severe 
symptoms.
The prevalence of HC use in elite female soccer players 
(28%) is similar to that of the general British (30%) (Cea- 
Soriano et al. 2014) and American (27.6%) public (Daniels 
et al., 2014) but less than in other elite female sports 
(47.1% and 49.5%) (Martin et al. 2018; Larsen et al. 2020). 
This lower prevalence might be accounted for by the infancy 
of the professional soccer game. Previous research indicates 
that athletes often manipulate and control their MC by using 
HCs (Schaumberg et al. 2018), and that elite (43%) versus 
sub-elite (22.5%) athletes are more likely to do this (Martin 
et al. 2018). In addition, this lower prevalence might be 
accounted for less severe symptoms in the non-HC group, 
meaning that they did not feel the need to use a HC in 
response to their symptoms. It will be interesting to track if 
more WSL players switch to using HCs to manipulate their 
MC in the coming years as the sport becomes more 
professional.
Most players anticipated negative symptoms before taking 
HCs (76%), with weight gain being the most common (33%) 
concern. Thirty-eight per cent experienced negative symp-
toms, with mood swings and still having a ‘period’, the 
most common issues (both 10%), and only one player report-
ing weight gain. Negative symptoms were most common in 
progestin only-HC users compared to combined HC users, 
which is a similar to previous findings (Martin et al. 2018). 
It is important to note that each pill formulation carriers its 
own unique concentration of synthetic hormones which 
needs to be considered when interpreting data. These pre- 
conceived ideas and lived experienced can be used to guide 
players to make informed HC choices.
Conclusion
This study is the first to audit HC and non-HC use in the 
WSL. Less than one-third of WSL players use a form of HC. 
Although most HC users reported benefits of HC use, it is 
not the intention of this paper to endorse or denounce HC 
use as we do not yet fully understand if the symptomatic 
benefits of HC result in any adverse health or performance- 
related consequences. Almost three-quarters of players 
reported negative symptoms during their MC, with 4% of 
players abstaining from training due to these unfavourable 
effects. These data can be used to inform support staff 
about the hormonal profile of women’s soccer players and 
to consider interventions in line with the demands and 
features of their sport.
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